Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory (2021 - 2025)

Apellis Pharmaceuticals has reported Inventory over the past 5 years, most recently at $142.6 million for Q4 2025.

  • Quarterly results put Inventory at $142.6 million for Q4 2025, up 75.12% from a year ago — trailing twelve months through Dec 2025 was $142.6 million (up 75.12% YoY), and the annual figure for FY2025 was $142.6 million, up 75.12%.
  • Inventory for Q4 2025 was $142.6 million at Apellis Pharmaceuticals, up from $122.8 million in the prior quarter.
  • Over the last five years, Inventory for APLS hit a ceiling of $161.3 million in Q1 2024 and a floor of $1.7 million in Q3 2021.
  • Median Inventory over the past 5 years was $85.7 million (2022), compared with a mean of $87.8 million.
  • Biggest five-year swings in Inventory: soared 3463.09% in 2022 and later plummeted 48.87% in 2025.
  • Apellis Pharmaceuticals' Inventory stood at $16.3 million in 2021, then soared by 426.3% to $85.7 million in 2022, then skyrocketed by 70.76% to $146.4 million in 2023, then crashed by 44.38% to $81.4 million in 2024, then skyrocketed by 75.12% to $142.6 million in 2025.
  • The last three reported values for Inventory were $142.6 million (Q4 2025), $122.8 million (Q3 2025), and $121.0 million (Q2 2025) per Business Quant data.